GenomedS.A.
Research and experimental development in natural sciences and engineering
Overview
Genomed is a company that provides genetic diagnostics based on DNA sequencing and offers services for scientific research. It specializes in the analysis of any gene and also provides oligonucleotide synthesis. Additionally, Genomed is involved in personalized medicine and genome analysis.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 37.20
- High
- PLN 37.20
- Low
- PLN 37.20
- Volume
- 15
- Avg. vol.
- 30.5
- Market cap
- PLN 49.15M
- P/E ratio
- 15.25
- EPS
- PLN 2.44
- Shares outstanding
- 1.32M
- 52-week
- PLN 35.40 – 37.80
- Dividend yield
- 4.03%
- Dividend
- PLN 1.50
- Ex dividend date
- Jul 6, 2026
- ISIN
- PLGNOMD00024
- Exchange
- NewConnect
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 1.93m | USD 165.32k | USD 123.99k |
| Q1 2026 | USD 1.83m | USD -4.05k | USD -13.24k |
| Q4 2025 | USD 2.20m | USD 512.81k | USD 408.84k |
| Q3 2025 | USD 2.00m | USD 434.46k | USD 358.11k |
Results for Q3 2026:Nov 13, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Industry
Bank accounts
Registered as a VAT taxpayer on 2007-09-12. Active
24 1600 1462 1002 0282 6000 0001- 94 1600 1462 1002 0282 6000 0002
- 10 1600 1374 0003 0052 0282 6150
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 9, 2017 | Bankruptcy notice | |
| Oct 5, 2012 | Commercial Companies Code notice |
Public aid
10 public aid cases recorded, with a total value of $857,098.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 15, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $204.6K$204,626 | Polski Fundusz Rozwoju S.A. | |
| Jul 13, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $2,116$2,116 | Prezydent Miasta Stołecznego Warszawy | |
| Jul 13, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $1,566$1,566 | Prezydent Miasta Stołecznego Warszawy |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2016-10-01 | Opracowanie metod nieinwazyjnej diagnostyki genetycznej i profilaktyki chorób nowotworowych - płynnej biopsji. | $525.3K$525,286 | Regionalny Program Operacyjny Województwa Mazowieckiego na lata 2014-2020 |
Tenders
77 tenders recorded as contractor: 57 national ($1,297,469) and 20 EU ($7,695,975).
| Publication date | Subject | Amount | Contracting authority | |
|---|---|---|---|---|
| Aug 14, 2026 | Dostawa odczynników chemicznych na potrzeby Centralnego Laboratorium Głównego Inspektoratu Ochrony Roślin i Nasiennictwa - ogłoszenie dotyczy części 26-39. | $125.3K$125,313 | Centrum Obsługi Administracji Rządowej | |
| Aug 3, 2026 | Usługa sekwencjonowania NGS (ang. Next Generation Sequencing) | $864.3K$864,293 | Narodowy Instytut Leków | |
| Jul 24, 2026 | Dostawa odczynników chemicznych do badań i analiz laboratoryjnych dla Wojewódzkiego Inspektoratu Weterynarii w Gdańsku - 11 części | $89,888$89,888 | Wojewódzki Inspektorat Weterynarii w Gdańsku |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The company may be represented by two members of the management board acting jointly or by a member of the management board acting with a commercial proxy.
Supervisory board
Beneficial owners
| Person | Rights |
|---|---|
Marek Zagulski (63)  | Shareholder of a joint-stock company, 27.45% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Polpharma BiologicsS.A. | $19,057,541.37 | polpharmabiologics.com | ||
| Scope FluidicsS.A. | $3,082,936.61 | scopefluidics.com | ||
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| Eurxsp. z o.o. | $1,644,555.44 | eurx.com.pl | ||
| Medsource Polskasp. z o.o. | $1,620,329.12 | medsource.com.pl | ||
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| BiokineticaS.A. | $1,292,838.89 | biokinetica.com | ||
| Saventic Healthsp. z o.o. | $1,089,246.05 | saventic.com |
Change history
| Date | Event | |
|---|---|---|
| 2015-04-24 | PKD change (Removed: 18.20.Z, 20.13.Z, 20.15.Z, 20.16.Z, 21.10.Z, 21.20.Z, 28.99.Z, 32.50.Z, 32.99.Z, 33.13.Z, 33.14.Z, 33.20.Z, 46.75.Z, 46.76.Z, 58.11.Z, 58.14.Z, 58.19.Z, 58.21.Z, 58.29.Z, 62.01.Z, 62.03.Z, 63.12.Z, 63.99.Z, 71.20.A, 74.90.Z, 77.40.Z, 82.99.Z, 86.10.Z, 86.21.Z) | |
| 2011-04-12 | Share capital change (121,900.00 PLN → 132,130.10 PLN) | |
| 2010-12-30 | Entered in the register |
FAQ
Last updated: 2026-07-24